Exelon Corporation (EXC) reported fourth-quarter and full-year 2009 earnings per share (EPS) of 92 cents and $4.12, respectively, above the Zacks Consensus Estimate of 85 cents and $4.04. However, it fell short of the year-ago...
Read MoreRecently, Bionovo, Inc. (BNVI) published results from the early-stage study of Bezielle (BZL101), its candidate for treating metastatic breast cancer. The results indicated that Bezielle was well tolerated and also confirmed the...
Read MoreIT bellwether International Business Machines Corp. (IBM) is set to release its fourth-quarter of 2009 earnings on Jan. 19. We do not expect the earnings to be a major catalyst for the stock price movement, but our focus will be...
Read MoreCutera, Inc. (CUTR) recently reported preliminary revenue results for its fourth quarter. For the quarter, Cutera expects revenues to be roughly $15 million, compared to $17.9 million in the year-ago period. The company is...
Read MoreStryker Corporation (SYK) reported preliminary revenue results for the fourth quarter and full fiscal 2009. For the fourth quarter, net sales were $1,834 million, an increase of 6.8% year over year. Excluding a favorable foreign...
Read MoreYesterday, Celgene Corporation (CELG) announced preliminary (unaudited) results for the fourth quarter of fiscal 2009 (ended December 31). The company earned 62 cents per share, beating the Zacks Consensus Estimate by 5 cents....
Read MoreThanks to all that participated in the ‘Trader’s Poll’ over the last few weeks. The question was “What are most important factors for ’successful’ trading?” From a total of 136 respondents, there was a clear trend in what people...
Read MoreAbiomed, Inc. (ABMD) reported preliminary results for the third quarter of fiscal 2010. Total revenues were roughly $22.8 million, an increase of 32% year over year and were at a record high. The company will report full results...
Read MoreKarsan Value Funds (KVF) is a value-oriented fund, as described here. Though some readers have expressed an interest in investing, due to securities regulations the fund is not open to the public at this time. Should that change...
Read MoreRecently, Array BioPharma Inc. (ARRY) announced positive interim results on its inhibitor, ARRY-380, from an early-stage, open-label, multiple dose trial in patients with advanced cancer. The company presented the results at the...
Read More
